Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.

Abstract

BACKGROUND:

Papillary and follicular thyroid carcinomas can be treated surgically and with radioiodine therapy, whereas therapeutic options for advanced stage IV medullary and for anaplastic tumours are limited. Recently, somatostatin receptors (SSTs) and the chemokine receptor CXCR4 have been evaluated for the treatment of thyroid carcinomas, however, with contradictory results.

METHODS:

The expression of the five SSTs and of CXCR4 was assessed in 90 samples from 56 patients with follicular, papillary, medullary, or anaplastic thyroid carcinoma by means of immunohistochemistry using well-characterised monoclonal antibodies. The stainings were evaluated using the Immunoreactivity Score (IRS) and correlated to clinical data. In order to further substantiate the immunohistochemistry results, in serial sections of a subset of the samples receptor expression was additionally examined at the mRNA level using qRT-PCR.

RESULTS:

Overall, SST and CXCR4 protein expression was low in all four entities. In single cases, however, very high IRS values for SST2 and CXCR4 were observed. SST2 was the most frequently expressed receptor, found in 38% of cases, followed by SST5 and SST4, found in 14 and 9% of tumours, respectively. SST1 and SST3 could not be detected to any significant extent. CXCR4 was present in 12.5% of medullary and 25% of anaplastic carcinomas. Expression SST3, SST4, SST5 and CXCR4 was positively correlated with expression of the proliferation marker Ki-67. Additionally, a negative interrelationship between SST4 or SST5 expression and patient survival and a positive association between SST3 expression and tumour diameter were observed. qRT-PCR revealed a similar receptor expression pattern to that seen at the protein level. However, probably due to the low overall expression, no correlation was found for the SSTs or the CXCR4 between the IRS and the mRNA values.

CONCLUSIONS:

SST- or CXCR4-based diagnostics or therapy in thyroid carcinomas should not be considered in general but may be feasible in single cases with high levels of expression of these receptors.

• Authors: Max Czajkowski, Daniel Kaemmerer, Jörg Sänger, Guido Sauter, Ralph M Wirtz, Stefan Schulz, Amelie Lupp
• Journal: BMC cancer (BMC Cancer) Vol. 22 Issue 1 Pg. 740 (Jul 07 2022) ISSN: 1471-2407 [Electronic] England
• PMID: 35799158 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Antibodies, Monoclonal
• CXCR4 protein, human
• Iodine Radioisotopes
• RNA, Messenger
• Receptors, CXCR4
• Receptors, Somatostatin

Topics

• Antibodies, Monoclonal
• Humans
• Iodine Radioisotopes
• RNA, Messenger (metabolism)
• Receptors, CXCR4 (genetics, metabolism)
• Receptors, Somatostatin (genetics, metabolism)
• Thyroid Neoplasms (genetics)